The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Rezdiffra is used in adults to treat nonalcoholic steatohepatitis (NASH) in certain situations, along with diet and exercise. NASH involves a buildup of fat in your liver that can cause ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional ...

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

Madrigal’s MASH treatment Rezdiffra receives EU approvalAnalyst activity has been notable, with Goldman Sachs reiterating a Buy rating and a $567 price target for Madrigal Pharmaceuticals. Piper ...

The first European launch of Rezdiffra is expected in the fourth quarter of 2025, starting with Germany. The drug is already included in European MASH treatment guidelines as a first-line treatment.

Rezdiffra is already included in European MASH treatment guidelines as a first-line treatment Madrigal is planning for its first European launch in Germany in the fourth quarter of 2025 ...

Rezdiffra’s Market Performance Rezdiffra has demonstrated strong market acceptance since its launch, with prescription rates steadily increasing. According to recent surveys, the drug’s prescription ...